EP2029743A4 - Methods of diagnosing and treating complications of pregnancy - Google Patents

Methods of diagnosing and treating complications of pregnancy

Info

Publication number
EP2029743A4
EP2029743A4 EP07795515A EP07795515A EP2029743A4 EP 2029743 A4 EP2029743 A4 EP 2029743A4 EP 07795515 A EP07795515 A EP 07795515A EP 07795515 A EP07795515 A EP 07795515A EP 2029743 A4 EP2029743 A4 EP 2029743A4
Authority
EP
European Patent Office
Prior art keywords
pregnancy
diagnosing
methods
treating complications
complications
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07795515A
Other languages
German (de)
French (fr)
Other versions
EP2029743A1 (en
Inventor
S Ananth Karumanchi
Vikas P Sukhatme
Mourad Toporsian
Michelle V Letarte
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hospital for Sick Children HSC
Beth Israel Deaconess Medical Center Inc
Original Assignee
Hospital for Sick Children HSC
Beth Israel Deaconess Medical Center Inc
Beth Israel Hospital Association
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/443,920 external-priority patent/US7740849B2/en
Application filed by Hospital for Sick Children HSC, Beth Israel Deaconess Medical Center Inc, Beth Israel Hospital Association filed Critical Hospital for Sick Children HSC
Publication of EP2029743A1 publication Critical patent/EP2029743A1/en
Publication of EP2029743A4 publication Critical patent/EP2029743A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
EP07795515A 2006-05-31 2007-05-31 Methods of diagnosing and treating complications of pregnancy Withdrawn EP2029743A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/443,920 US7740849B2 (en) 2004-09-24 2006-05-31 Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US85276106P 2006-10-19 2006-10-19
PCT/US2007/012787 WO2008030283A1 (en) 2006-05-31 2007-05-31 Methods of diagnosing and treating complications of pregnancy

Publications (2)

Publication Number Publication Date
EP2029743A1 EP2029743A1 (en) 2009-03-04
EP2029743A4 true EP2029743A4 (en) 2010-12-08

Family

ID=39157545

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07795515A Withdrawn EP2029743A4 (en) 2006-05-31 2007-05-31 Methods of diagnosing and treating complications of pregnancy

Country Status (9)

Country Link
EP (1) EP2029743A4 (en)
JP (1) JP2009538915A (en)
KR (1) KR20090040874A (en)
CN (1) CN101517078A (en)
AU (1) AU2007293475A1 (en)
BR (1) BRPI0713122A2 (en)
CA (1) CA2654283A1 (en)
MX (1) MX2008015197A (en)
WO (1) WO2008030283A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE488251T1 (en) 2004-09-24 2010-12-15 Beth Israel Hospital METHOD FOR DIAGNOSIS AND TREATMENT OF PREGNANCY COMPLICATIONS
US7740849B2 (en) 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
WO2007053161A2 (en) 2004-12-15 2007-05-10 Beth Israel Deaconess Medical Center Nucleic acids and polypeptides useful for diagnosing and treating complications of pregnancy
US20100016173A1 (en) * 2008-01-30 2010-01-21 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
EP2300825A4 (en) * 2008-06-18 2012-04-25 Abbott Lab P/gf-1 companion diagnostic methods and products
CN102414566B (en) * 2009-04-23 2015-04-01 沃莱克公司 Methods for determining maternal health risks
MX2012011007A (en) * 2010-03-24 2013-03-20 Preelumina Diagnostics Ab Hbf and a1m as early stage markers for preeclampsia.
US20110251094A1 (en) 2010-04-13 2011-10-13 Pronota N.V. Biomarkers for hypertensive disorders of pregnancy
AU2011240039B2 (en) * 2010-04-13 2017-01-19 Mycartis Nv Biomarkers for hypertensive disorders of pregnancy
EP3248946B1 (en) 2010-05-14 2021-02-24 Beth Israel Deaconess Medical Center, Inc. Extracorporeal devices and methods of treating complications of pregnancy
CN102058435B (en) * 2011-01-17 2012-05-09 北京工业大学 Monitor for gestational hypertension risk on basis of physiology, biochemistry and blood dynamics information
EP2726631A1 (en) 2011-06-28 2014-05-07 Vitateq Biotechnology GmbH Method for diagnosing preeclampsia
CN104011069A (en) * 2011-08-01 2014-08-27 塔夫茨医学中心有限公司 Treatment of heat failure and related conditions
WO2014036440A2 (en) * 2012-08-30 2014-03-06 Ansh Labs Llc Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia
KR101417379B1 (en) * 2012-10-30 2014-07-10 곽호석 Diagnostic methods for Fetal Lung Maturity using Mass Spectrometer
CN103235142B (en) * 2013-04-28 2015-04-15 成都中医药大学 First pregnancy screening kit for pregnant woman
CN103207274B (en) * 2013-04-28 2015-02-25 成都中医药大学 Screening kit for seventh chromosome abnormality diseases of fetus
MX2018011739A (en) * 2016-03-31 2018-12-19 Immutrix Therapeutics Inc Method for extracorporeal treatment of preeclampsia and related disorders.
CN113919453B (en) * 2021-09-13 2024-06-11 深圳大学龙华生物产业创新研究院 Blockchain integration system for recording biological characteristics
CN113933129B (en) * 2021-09-14 2024-01-12 深圳大学 Preeclampsia diagnosis kit and application of fluorescent dye
CN115791340B (en) * 2023-01-17 2023-05-02 北京水木济衡生物技术有限公司 Epilepsy composite quality control product and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034507A2 (en) * 2004-09-24 2006-03-30 Beth Israel - Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020031513A1 (en) * 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
HUP0200799A3 (en) * 1999-04-16 2004-11-29 Univ Yale New Haven Enos mutations useful for gene therapy and therapeutic screening
WO2002086497A2 (en) * 2001-04-24 2002-10-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006034507A2 (en) * 2004-09-24 2006-03-30 Beth Israel - Deaconess Medical Center Methods of diagnosing and treating complications of pregnancy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2008030283A1 *

Also Published As

Publication number Publication date
BRPI0713122A2 (en) 2012-04-17
JP2009538915A (en) 2009-11-12
MX2008015197A (en) 2009-06-23
WO2008030283A1 (en) 2008-03-13
EP2029743A1 (en) 2009-03-04
CN101517078A (en) 2009-08-26
CA2654283A1 (en) 2008-03-13
AU2007293475A1 (en) 2008-03-13
KR20090040874A (en) 2009-04-27

Similar Documents

Publication Publication Date Title
EP2029743A4 (en) Methods of diagnosing and treating complications of pregnancy
EP2234483A4 (en) Methods and compositions for diagnosing complications of pregnancy
EP2027602A4 (en) Lighting device and method of making
TWI372796B (en) Sapphire substrates and methods of making same
TWI350784B (en) Sapphire substrates and methods of making same
EP2029936A4 (en) Lighting device and method of lighting
IL197721A0 (en) Compositions and methods for diagnosing and treating cancer
PL2032166T3 (en) Compositions and methods for diagnosing and treating cancer
EP2088952A4 (en) Methods and devices for treating tissue
IL195400A0 (en) Aldh-2 inhibitors in the treatment of addiction
HK1123961A1 (en) Tissue fasteners and related insertion devices
ZA200807590B (en) Diagnostics and treatments for tumors
SI2520295T1 (en) Methods for preventing and treating mucositis
GB0603295D0 (en) Methods and kits
EP1909911A4 (en) Methods and compositions for improving pregnancy outcome
GB0608647D0 (en) Methods of diagnosis and treatment
GB0601557D0 (en) Vehicle and method of modification thereof
EP2091551A4 (en) Method of diagnosing and treating asthma
EP2171086A4 (en) Methods of diagnosing and treating cancer
EP1859725A4 (en) Endoscope and method of repairing endoscope
HK1157672A1 (en) Lash enhancement composition and method of treatment
GB0613970D0 (en) Vehicle and method of modification thereof
EP1906969A4 (en) Methods for treating and diagnosing complications of premature birth
EP2099933A4 (en) Hypoxia related genes and proteins for the treatment and diagnosis of pregnancy related complications
EP2099491A4 (en) Compositions and methods for diagnosing and treating cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE HOSPITAL FOR SICK CHILDREN

Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE HOSPITAL FOR SICK CHILDREN

Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1125675

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20101109

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110607

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1125675

Country of ref document: HK